Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh‐Navikas, Hans Skovgaard Poulsen, Ulrik LassenMolecular 2016 · DOI

Abstract

Two genes (low angiotensinogen and high HLA-class II expression) were predictive for bevacizumab response and were included in a predictive model for response. This model can be used in clinical practice to identify patients who will benefit from bevacizumab combination therapy.
BibTeX
@inproceedings{urup2016angiotensinogen,
  author = {Thomas Urup and Signe Regner Michaelsen and Lars Rønn Olsen and Anders Toft and Ib Jarle Christensen and Kirsten Grunnet and Ole Winther and Helle Broholm and Michael Kosteljanetz and Shohreh Issazadeh‐Navikas and Hans Skovgaard Poulsen and Ulrik Lassen},
  title = {{Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients}},
  booktitle = {Molecular},
  year = {2016},
  doi = {10.1016/j.molonc.2016.05.005},
}

Loading related content...

Figure